Maxim Norkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maxim Norkin has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- John R. Wingard
University of Florida Department of Medicine Gainesville, Florida
36 shared publications John R. Wingard
University of Florida, United States
5 shared publicationsHillard M. Lazarus
Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland, Ohio
4 shared publicationsChristopher R. Cogle
University of Florida, United States
3 shared publicationsMahmoud Aljurf
Adult HSCT Program, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3 shared publicationsPeiman Hematti
Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin
3 shared publications
Latest Publications
- Open Access
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 2-4
HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents
Background: Patients with RRMM receive multiple lines of therapy in their disease course and often become refractory to or are intolerant of newer approved therapies (eg, IMiDs, anti-CD38 monoclonal antibody [mAb] therapy, proteasome inhibitors [PIs]), limiting effective treatment options (Kumar et al. Leukemia. 2017; 31:2443). Efficacy outcomes decrease with each line of therapy, showing a need for agents with novel mechanisms of action to improve treatment responses and survival outcomes (Gandhi et al. Leukemia. 2019;33:2266). Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. In the phase 2 HORIZON study (OP-106; NCT02963493), melflufen plus dexamethasone demonstrated encouraging efficacy in heavily pretreated patients with RRMM refractory to pomalidomide and/or an anti-CD38 mAb (overall response rate [ORR], 29%; median progression-free survival [PFS], 4.2 months; median overall survival [OS], 11.6 months) with a clinically manageable safety profile characterized primarily by hematologic adverse events (Richardson et al. EHA 2020. Abs. EP945). A contemporary representative control cohort is often used to indirectly compare outcomes of patients in clinical trials versus real-world data. The retrospective MAMMOTH study investigated the natural history and outcomes of patients with RRMM refractory to anti-CD38 mAb therapy after treatment with conventional agents (Gandhi et al. Leukemia. 2019;33:2266), providing a benchmark for the evolving state of the RRMM treatment landscape. Outcomes in clinical studies of novel agents in RRMM have been compared with MAMMOTH previously (Costa et al. ASH 2019. Abs. 3125), but not specifically in patients with RRMM refractory to anti-CD38 mAb therapy. To contextualize the clinical benefit of melflufen plus dexamethasone compared with conventional agents for patients with RRMM refractory to anti-CD38 mAb therapy, an analysis was conducted evaluating efficacy outcomes in HORIZON versus MAMMOTH. Methods: HORIZON patients with RRMM refractory to anti-CD38 mAb in the last line of therapy in the intention-to-treat population at final analysis (data cutoff date, 14 Jan 2020) were included in this analysis (N=63). Patients received melflufen 40 mg (intravenously on day 1 of each 28-day cycle) plus dexamethasone 40 mg weekly until disease progression or unacceptable toxicity. The MAMMOTH dataset included patients who progressed while on anti-CD38 mAb therapy (N=275) and were subsequently treated (N=249). ORR was assessed by the investigator per the International Myeloma Working Group criteria. PFS was defined as the time between the first dose of therapy and disease progression or death. OS was defined as the time from refractoriness to anti-CD38 mAb therapy to death from any cause in contrast to clinical studies in which OS is generally measured from first dose of subsequent therapy. Results: Patients in HORIZON and MAMMOTH had similar baseline median age and profile of daratumumab and isatuximab refractoriness (Table). Patients in HORIZON were more heavily pretreated than those in MAMMOTH (median number of prior therapies [range], 5 [2-10] versus 4 [1-16]). Patients in MAMMOTH were often treated with triplet therapy as first subsequent therapy after anti-CD38 mAb therapy failure (Table). ORR for HORIZON patients who failed last-line therapy with an anti-CD38 mAb (N=63) was 35% versus 31% for all anti-CD38 mAb therapy-refractory patients who received conventional agents in MAMMOTH. Median PFS was 4.6 months (95% CI, 3.7-6.4) versus 3.4 months (95% CI, 2.8-4.0), and median OS from last line was 15.4 months (95% CI, 12.0-25.6) versus 9.3 months (95% CI, 8.1-10.6) for these patients in HORIZON and MAMMOTH, respectively. Conclusion: This indirect comparison of patients with RRMM refractory to anti-CD38 mAb therapy in HORIZON and MAMMOTH suggests longer survival outcomes with melflufen plus dexamethasone (median PFS and OS of 4.6 and 15.4 months, respectively) versus those with conventional agents, despite HORIZON having more heavily pretreated patients. This analysis underscores the high burden of disease and unmet needs for patients with RRMM and the feasibility of novel combination therapy in this setting.
- 5 November 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (Supplement) , 2-4
Open AccessHORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents
Background: Patients with RRMM receive multiple lines of therapy in their disease course and often become refractory to or are intolerant of newer approved therapies (eg, IMiDs, anti-CD38 monoclonal antibody [mAb] therapy, proteasome inhibitors [PIs]), limiting effective treatment options (Kumar et al. Leukemia. 2017; 31:2443). Efficacy outcomes decrease with each line of therapy, showing a need for agents with novel mechanisms of action to improve treatment responses and survival outcomes (Gandhi et al. Leukemia. 2019;33:2266). Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. In the phase 2 HORIZON study (OP-106; NCT02963493), melflufen plus dexamethasone demonstrated encouraging efficacy in heavily pretreated patients with RRMM refractory to pomalidomide and/or an anti-CD38 mAb (overall response rate [ORR], 29%; median progression-free survival [PFS], 4.2 months; median overall survival [OS], 11.6 months) with a clinically manageable safety profile characterized primarily by hematologic adverse events (Richardson et al. EHA 2020. Abs. EP945). A contemporary representative control cohort is often used to indirectly compare outcomes of patients in clinical trials versus real-world data. The retrospective MAMMOTH study investigated the natural history and outcomes of patients with RRMM refractory to anti-CD38 mAb therapy after treatment with conventional agents (Gandhi et al. Leukemia. 2019;33:2266), providing a benchmark for the evolving state of the RRMM treatment landscape. Outcomes in clinical studies of novel agents in RRMM have been compared with MAMMOTH previously (Costa et al. ASH 2019. Abs. 3125), but not specifically in patients with RRMM refractory to anti-CD38 mAb therapy. To contextualize the clinical benefit of melflufen plus dexamethasone compared with conventional agents for patients with RRMM refractory to anti-CD38 mAb therapy, an analysis was conducted evaluating efficacy outcomes in HORIZON versus MAMMOTH. Methods: HORIZON patients with RRMM refractory to anti-CD38 mAb in the last line of therapy in the intention-to-treat population at final analysis (data cutoff date, 14 Jan 2020) were included in this analysis (N=63). Patients received melflufen 40 mg (intravenously on day 1 of each 28-day cycle) plus dexamethasone 40 mg weekly until disease progression or unacceptable toxicity. The MAMMOTH dataset included patients who progressed while on anti-CD38 mAb therapy (N=275) and were subsequently treated (N=249). ORR was assessed by the investigator per the International Myeloma Working Group criteria. PFS was defined as the time between the first dose of therapy and disease progression or death. OS was defined as the time from refractoriness to anti-CD38 mAb therapy to death from any cause in contrast to clinical studies in which OS is generally measured from first dose of subsequent therapy. Results: Patients in HORIZON and MAMMOTH had similar baseline median age and profile of daratumumab and isatuximab refractoriness (Table). Patients in HORIZON were more heavily pretreated than those in MAMMOTH (median number of prior therapies [range], 5 [2-10] versus 4 [1-16]). Patients in MAMMOTH were often treated with triplet therapy as first subsequent therapy after anti-CD38 mAb therapy failure (Table). ORR for HORIZON patients who failed last-line therapy with an anti-CD38 mAb (N=63) was 35% versus 31% for all anti-CD38 mAb therapy-refractory patients who received conventional agents in MAMMOTH. Median PFS was 4.6 months (95% CI, 3.7-6.4) versus 3.4 months (95% CI, 2.8-4.0), and median OS from last line was 15.4 months (95% CI, 12.0-25.6) versus 9.3 months (95% CI, 8.1-10.6) for these patients in HORIZON and MAMMOTH, respectively. Conclusion: This indirect comparison of patients with RRMM refractory to anti-CD38 mAb therapy in HORIZON and MAMMOTH suggests longer survival outcomes with melflufen plus dexamethasone (median PFS and OS of 4.6 and 15.4 months, respectively) versus those with conventional agents, despite HORIZON having more heavily pretreated patients. This analysis underscores the high burden of disease and unmet needs for patients with RRMM and the feasibility of novel combination therapy in this setting.
- Open Access
- 1 July 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (7) , 1424-1431
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning
- 1 July 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (7) , 1424-1431
Open AccessAssociation of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning
- Open Access
- 1 July 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (7) , 1325-1330
The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time
- 1 July 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (7) , 1325-1330
Open AccessThe Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time
- Open Access
- 1 March 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (3) , 480-487
Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation
- 1 March 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (3) , 480-487
Open AccessEffect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation
- Open Access
- 1 February 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (2) , 362-368
Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
- 1 February 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (2) , 362-368
Open AccessCharacteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
- 20 December 2018
- Published by H1 Connect
Faculty Opinions recommendation of Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation.
Vancomycin-resistant enterococcus (VRE) bacteremia (VREB) remains a significant cause of morbidity and mortality in allogeneic stem cell transplant (allo-HCT) recipients, particularly during the pre-engraftment period. It is well known that VRE colonization both antedates and substantially increases the risk of VREB in immunosuppressed patients. Therefore, VRE-directed therapy is frequently incorporated into the empiric antibiotic regimen given for neutropenic fever in VRE-colonized allo-HCT recipients; however, the efficacy of this approach on clinical outcomes and mortality is not known. In this large retrospective single-institution study, the efficacy of empiric VRE therapy with linezolid was compared to VRE therapy initiated when Gram-positive cocci were identified in blood cultures in adult allo-HCT recipients with known VRE colonization during the pre-engraftment period. Out of 1306 evaluated patients, 434 (33%) were VRE-colonized. Out of these 434 patients, 172 patients (40%) received empiric therapy with linezolid. The incidence of VREB in the empiric VRE therapy as compared to no empiric therapy was similar (16% vs 21%; P=0.22), with most VREB episodes in the empiric VRE therapy group occurring on the same day as the initiation of linezolid. No significant differences in median duration of bacteremia (2 vs 2 days, P=0.39) or recurrence (10% vs 8%, P=0.65) of VREB were observed. Importantly, there were no differences in VRE-attributable mortality (3% vs 2%, P=0.55) nor 30-day (3% vs 6% P=0.62) or 60-day (14% vs 12% P=0.84) all-cause mortality in patients who received or did not receive empiric therapy with linezolid. These data show a lack of clinical benefit of empiric linezolid therapy in VRE-colonized allo-HCT patients during the pre-engraftment period. Therefore, the empiric use of antimicrobial agents against VRE in VRE-colonized allo-HSCT recipients with febrile neutropenia can not be recommended, especially since overuse of antibiotics may lead to the emergence of additional drug resistance. Why empiric therapy against VRE failed to improve clinical outcomes and mortality in these patients is unclear. One consideration not mentioned by the authors is the possibility that rapid notification of blood culture results may have led to only a small delay in initiation of treatment in the directed treatment group. Another possible explanation that the authors suggest is that perhaps the morbidity associated with the occurrence of VRE may be more related to host factors, such as gut mucosal damage or neutropenia duration rather than the pathogen itself.
- 20 December 2018
- Published by H1 Connect
Faculty Opinions recommendation of Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation.
Vancomycin-resistant enterococcus (VRE) bacteremia (VREB) remains a significant cause of morbidity and mortality in allogeneic stem cell transplant (allo-HCT) recipients, particularly during the pre-engraftment period. It is well known that VRE colonization both antedates and substantially increases the risk of VREB in immunosuppressed patients. Therefore, VRE-directed therapy is frequently incorporated into the empiric antibiotic regimen given for neutropenic fever in VRE-colonized allo-HCT recipients; however, the efficacy of this approach on clinical outcomes and mortality is not known. In this large retrospective single-institution study, the efficacy of empiric VRE therapy with linezolid was compared to VRE therapy initiated when Gram-positive cocci were identified in blood cultures in adult allo-HCT recipients with known VRE colonization during the pre-engraftment period. Out of 1306 evaluated patients, 434 (33%) were VRE-colonized. Out of these 434 patients, 172 patients (40%) received empiric therapy with linezolid. The incidence of VREB in the empiric VRE therapy as compared to no empiric therapy was similar (16% vs 21%; P=0.22), with most VREB episodes in the empiric VRE therapy group occurring on the same day as the initiation of linezolid. No significant differences in median duration of bacteremia (2 vs 2 days, P=0.39) or recurrence (10% vs 8%, P=0.65) of VREB were observed. Importantly, there were no differences in VRE-attributable mortality (3% vs 2%, P=0.55) nor 30-day (3% vs 6% P=0.62) or 60-day (14% vs 12% P=0.84) all-cause mortality in patients who received or did not receive empiric therapy with linezolid. These data show a lack of clinical benefit of empiric linezolid therapy in VRE-colonized allo-HCT patients during the pre-engraftment period. Therefore, the empiric use of antimicrobial agents against VRE in VRE-colonized allo-HSCT recipients with febrile neutropenia can not be recommended, especially since overuse of antibiotics may lead to the emergence of additional drug resistance. Why empiric therapy against VRE failed to improve clinical outcomes and mortality in these patients is unclear. One consideration not mentioned by the authors is the possibility that rapid notification of blood culture results may have led to only a small delay in initiation of treatment in the directed treatment group. Another possible explanation that the authors suggest is that perhaps the morbidity associated with the occurrence of VRE may be more related to host factors, such as gut mucosal damage or neutropenia duration rather than the pathogen itself.
- 1 November 2018
- Published by Elsevier in Leukemia Research
- Vol. 74, 110-112
CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation
- 1 November 2018
- Published by Elsevier in Leukemia Research
- Vol. 74, 110-112
CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation
- 9 March 2018
- Published by H1 Connect
Faculty Opinions recommendation of Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.
High dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) has been increasingly utilized for patients with a variety of autoimmune disorders. The concept has a sound scientific basis for a potential therapy: immunoablation followed by infusion of autologous hematopoietic stem cells may lead to eradication of the autoreactive immunologic memory cells and reset a dysfunctional immune system in...
- 9 March 2018
- Published by H1 Connect
Faculty Opinions recommendation of Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis.
High dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) has been increasingly utilized for patients with a variety of autoimmune disorders. The concept has a sound scientific basis for a potential therapy: immunoablation followed by infusion of autologous hematopoietic stem cells may lead to eradication of the autoreactive immunologic memory cells and reset a dysfunctional immune system in...
- 9 March 2018
- Published by H1 Connect
Faculty Opinions recommendation of Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.
African American (AA) patients have inferior survival following hematopoietic stem cell transplant. The impact of race on post-HCT outcomes is not fully understood. Differences in socioeconomic status could be one of the reasons for inferior post-HCT outcomes in AA; however, blacks have higher overall mortality after HCT compared with whites even after adjustment for various combinations of socioeconomic indicators. Therefore, socioeconomic...
- 9 March 2018
- Published by H1 Connect
Faculty Opinions recommendation of Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.
African American (AA) patients have inferior survival following hematopoietic stem cell transplant. The impact of race on post-HCT outcomes is not fully understood. Differences in socioeconomic status could be one of the reasons for inferior post-HCT outcomes in AA; however, blacks have higher overall mortality after HCT compared with whites even after adjustment for various combinations of socioeconomic indicators. Therefore, socioeconomic...
- 9 March 2018
- Published by H1 Connect
Faculty Opinions recommendation of Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
Relapse of leukemia after allogeneic hematopoietic stem cell transplant (allo-HCT) remains a major obstacle to treatment success and cure. The graft versus leukemia (GVL) effect plays a crucial role in preventing disease relapse following allo-HCT. GVL is elicited through activation of mismatched allogenic antigen-specific T-cells, activated dendritic cells and natural killer (NK) cells. Strategies to boost GVL activity by enhancing activation of allogeneic T-cell effector functions often lead to unwanted exacerbation of graft versus host disease (GVHD). Despite extensive research, therapeutic strategies promoting and enhancing GVL responses without increasing the risks of GVHD are lacking. NK cells recover early after HCT and thus are candidates to exploit for antitumor activity. The current problem is that they are dysfunctional early after HCT. Manipulations that enhance NK activity through donor and recipient killer immunoglobulin-like receptors (KIR) mismatch or by adoptive transfer of NK cells after allo-HCT may potentially reduce risk relapse by promoting GVL without enhancing GVHD. In this article, the authors systematically reviewed approaches utilizing activated NK to reduce relapse risk after allo-HCT. Introductory information on NK cell biology, genetics and the role of the KIRs in NK cell activation and tolerance were followed by discussions on the impact of donor and recipient KIR genotype mismatch on acute GVHD and leukemia relapse after allo-HCT. Approaches involving adoptive transfer of unique subsets of allogenic NK cell followed by cytokine induced NK cell expansion were also reviewed. Finally, novel techniques promoting NK activation by using checkpoint modulators and NK activators such CD 16 stimulation were discussed. Better understanding of NK cell biology and NK mediated anti-leukemic activity alongside emerging data from ongoing or future clinical trials exploiting NK activation or adoptive transfer of expanded NK cells after allo-HCT will help to further exploit NK cell-mediated therapy as a therapeutic option to reduce relapse while avoiding GVHD in clinical practice.
- 9 March 2018
- Published by H1 Connect
Faculty Opinions recommendation of Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
Relapse of leukemia after allogeneic hematopoietic stem cell transplant (allo-HCT) remains a major obstacle to treatment success and cure. The graft versus leukemia (GVL) effect plays a crucial role in preventing disease relapse following allo-HCT. GVL is elicited through activation of mismatched allogenic antigen-specific T-cells, activated dendritic cells and natural killer (NK) cells. Strategies to boost GVL activity by enhancing activation of allogeneic T-cell effector functions often lead to unwanted exacerbation of graft versus host disease (GVHD). Despite extensive research, therapeutic strategies promoting and enhancing GVL responses without increasing the risks of GVHD are lacking. NK cells recover early after HCT and thus are candidates to exploit for antitumor activity. The current problem is that they are dysfunctional early after HCT. Manipulations that enhance NK activity through donor and recipient killer immunoglobulin-like receptors (KIR) mismatch or by adoptive transfer of NK cells after allo-HCT may potentially reduce risk relapse by promoting GVL without enhancing GVHD. In this article, the authors systematically reviewed approaches utilizing activated NK to reduce relapse risk after allo-HCT. Introductory information on NK cell biology, genetics and the role of the KIRs in NK cell activation and tolerance were followed by discussions on the impact of donor and recipient KIR genotype mismatch on acute GVHD and leukemia relapse after allo-HCT. Approaches involving adoptive transfer of unique subsets of allogenic NK cell followed by cytokine induced NK cell expansion were also reviewed. Finally, novel techniques promoting NK activation by using checkpoint modulators and NK activators such CD 16 stimulation were discussed. Better understanding of NK cell biology and NK mediated anti-leukemic activity alongside emerging data from ongoing or future clinical trials exploiting NK activation or adoptive transfer of expanded NK cells after allo-HCT will help to further exploit NK cell-mediated therapy as a therapeutic option to reduce relapse while avoiding GVHD in clinical practice.